7 March 2026 in Asia-Pacific Journal of Ophthalmology
Proliferative vitreoretinopathy (PVR) remains a major barrier in vitreoretinal surgery, being the leading cause of recurrent retinal detachment and surgical failure. PVR arises from abnormal wound healing, involving epithelial-mesenchymal transition (EMT) of retinal pigment epithelial cells, hyalocytes trans-differentiation into myofibroblasts, and dysregulated interactions among cytokines, growth factors, and chemokines. These lead to extracellular matrix remodeling and contractile membrane formation. Recent advancements have deepened insight into disease mechanisms and supported preclinical testing of therapies. Despite surgical progress, adjunctive treatments such as corticosteroids, antimetabolites, retinoids, and biologics show limited and inconsistent benefits in clinical trials. Emerging tools like proteomic biomarkers and advanced imaging offer promise for early risk detection and personalized care. However, major challenges remain in understanding disease complexity and improving tailored treatment outcomes. This review emphasizes the urgent need for targeted molecular therapies. Bridging basic science with clinical innovation will be key to advancing PVR management and preserving vision.
1 April 2026 in Patient Preference and Adherence
To assess whether preoperative viewing of an educational procedural video reduces the incidence and severity of subconjunctival hemorrhage (SCH) following intravitreal anti-VEGF injections (IVI), and improves patient experience. In this surgeon-blind randomized controlled trial conducted at a single tertiary care center (NCT07002372), treatment-naïve patients scheduled for their first IVI were prospectively enrolled and randomized to either an intervention group (video viewing) or a control group (no video viewing). All participants completed the State-Trait Anxiety Inventory-State (STAI-S) before and after the injection. SCH incidence and area were assessed via standardized post-injection photographs analyzed using ImageJ software. Additional outcomes included patient-reported pain scores, heart rate, procedure time, and surgeon-rated cooperation. A total of 108 patients were enrolled, of whom 103 completed the study, which was fewer than the initially planned sample size. Baseline demographics were similar between groups. SCH occurred in 21/51 (41.2%) patients in the intervention group versus 36/52 (69.2%) in the control group (P = 0.004), though SCH area did not differ significantly. Logistic regression analysis revealed that the use of anticoagulant medication was positively associated with the occurrence of SCH (OR = 3.252; 95% CI, 1.166–9.071; P = 0.024), whereas watching an educational video prior to IVI was associated with a lower risk of SCH (OR = 0.275; 95% CI, 0.115–0.656; P = 0.004). Anxiety scores decreased post-procedure in both groups. In the intervention group, anxiety decreased modestly after video viewing (28.54 ± 10.40 to 27.00 ± 8.78, P = 0.052). Patients rated the video as helpful for understanding (8.75/10), calming nerves (8.44/10), and improving cooperation (8.55/10). No significant differences were observed in pain scores, heart rate, procedure time, or surgeon-rated cooperation. Preoperative procedural video viewing reduces the incidence of SCH and improves patients’ understanding of IVI. Given its simplicity and ease of implementation, this approach may serve as a practical adjunct to enhance patient experience in clinical practice.